PACIRA BIOSCIENCES, INC. Operating Cash Flow
PACIRA BIOSCIENCES, INC. (PCRX) reported Operating Cash Flow of $83.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $57.46M, a 378.35% increase year-over-year.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $25.68M, a 27.58% decline year-over-year.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $43.69M, a 31.86% increase year-over-year.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $60.83M, a 12.82% increase year-over-year.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2025 was $151.99M, a 19.75% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2024 was $189.39M, a 22.46% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2023 was $154.65M, a 6.45% increase from fiscal 2022.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2022 was $145.27M, a 15.56% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $57.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $83.14M 10-Q · filed 2026-08-04 | $126.83M derived: sum of 3 quarters · filed 2026-08-04 | $187.66M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $25.68M 10-Q · filed 2026-04-30 | $69.37M derived: sum of 2 quarters · filed 2026-04-30 | $130.20M derived: sum of 3 quarters · filed 2026-04-30 | $142.22M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $43.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $104.52M derived: sum of 2 quarters · filed 2026-02-26 | $116.53M derived: sum of 3 quarters · filed 2026-08-04 | $151.99M 10-K · filed 2026-02-26 |
| 2025-09-30 | $60.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $72.85M derived: sum of 2 quarters · filed 2026-08-04 | $108.31M 10-Q · filed 2025-11-06 | $141.44M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $12.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $47.47M 10-Q · filed 2026-08-04 | $80.60M derived: sum of 3 quarters · filed 2026-08-04 | $134.52M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $35.46M 10-Q · filed 2026-04-30 | $68.59M derived: sum of 2 quarters · filed 2026-04-30 | $122.51M derived: sum of 3 quarters · filed 2026-04-30 | $175.75M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $33.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $87.05M derived: sum of 2 quarters · filed 2026-02-26 | $140.29M derived: sum of 3 quarters · filed 2026-02-26 | $189.39M 10-K · filed 2026-02-26 |
| 2024-09-30 | $53.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $107.16M derived: sum of 2 quarters · filed 2025-11-06 | $156.26M 10-Q · filed 2025-11-06 | $203.84M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $53.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $102.34M 10-Q · filed 2025-08-05 | $149.92M derived: sum of 3 quarters · filed 2026-02-26 | $194.36M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $49.10M 10-Q · filed 2025-05-08 | $96.69M derived: sum of 2 quarters · filed 2026-02-26 | $141.12M derived: sum of 3 quarters · filed 2026-02-26 | $184.62M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $47.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $92.02M derived: sum of 2 quarters · filed 2026-02-26 | $135.52M derived: sum of 3 quarters · filed 2026-02-26 | $154.65M 10-K · filed 2026-02-26 |
| 2023-09-30 | $44.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $87.94M derived: sum of 2 quarters · filed 2024-11-06 | $107.06M 10-Q · filed 2024-11-06 | $149.10M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $43.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $62.63M 10-Q · filed 2024-07-30 | $104.66M derived: sum of 3 quarters · filed 2025-02-27 | $147.32M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $19.13M 10-Q · filed 2024-05-07 | $61.16M derived: sum of 2 quarters · filed 2025-02-27 | $103.82M derived: sum of 3 quarters · filed 2025-02-27 | $133.63M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $42.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $84.69M derived: sum of 2 quarters · filed 2025-02-27 | $114.50M derived: sum of 3 quarters · filed 2025-02-27 | $145.27M 10-K · filed 2025-02-27 |
| 2022-09-30 | $42.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $72.46M derived: sum of 2 quarters · filed 2023-11-02 | $103.24M 10-Q · filed 2023-11-02 | $126.45M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $29.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $60.58M 10-Q · filed 2023-08-02 | $83.80M derived: sum of 3 quarters · filed 2024-02-29 | $144.09M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $30.78M 10-Q · filed 2023-05-03 | $53.99M derived: sum of 2 quarters · filed 2024-02-29 | $114.28M derived: sum of 3 quarters · filed 2024-02-29 | $144.41M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $23.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $83.50M derived: sum of 2 quarters · filed 2024-02-29 | $113.64M derived: sum of 3 quarters · filed 2024-02-29 | $125.72M 10-K · filed 2024-02-29 |
| 2021-09-30 | $60.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $90.42M derived: sum of 2 quarters · filed 2022-11-03 | $102.50M 10-Q · filed 2022-11-03 | $149.17M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $30.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $42.22M 10-Q · filed 2022-08-03 | $88.88M derived: sum of 3 quarters · filed 2023-02-28 | $128.66M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $12.08M 10-Q · filed 2022-05-04 | $58.75M derived: sum of 2 quarters · filed 2023-02-28 | $98.53M derived: sum of 3 quarters · filed 2023-02-28 | $82.91M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $46.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $86.45M derived: sum of 2 quarters · filed 2023-02-28 | $70.82M derived: sum of 3 quarters · filed 2023-02-28 | $77.03M 10-K · filed 2023-02-28 |
| 2020-09-30 | $39.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $24.16M derived: sum of 2 quarters · filed 2021-11-03 | $30.36M 10-Q · filed 2021-11-03 | $56.27M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$15.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$9.42M 10-Q · filed 2021-08-03 | $16.49M derived: sum of 3 quarters · filed 2022-02-28 | $34.84M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $6.21M 10-Q · filed 2021-05-04 | $32.11M derived: sum of 2 quarters · filed 2022-02-28 | $50.47M derived: sum of 3 quarters · filed 2022-02-28 | $73.23M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $25.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $44.26M derived: sum of 2 quarters · filed 2022-02-28 | $67.02M derived: sum of 3 quarters · filed 2022-02-28 | $70.52M 10-K · filed 2022-02-28 |
| 2019-09-30 | $18.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $41.12M derived: sum of 2 quarters · filed 2020-10-30 | $44.62M 10-Q · filed 2020-10-30 | $65.84M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $22.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $26.26M 10-Q · filed 2020-08-06 | $47.48M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2019-03-31 | $3.50M 10-Q · filed 2020-05-07 | $24.72M derived: sum of 2 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $21.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $48.87M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $27.65M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | $17.79M 10-K · filed 2020-02-21 | |||
| 2011-06-30 | -$14.91M 10-Q · filed 2011-08-11 | |||
| 2010-06-30 | -$12.13M 10-Q · filed 2011-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |